1. 职称：教授，研究员
2. 学历：博士
3. 研究方向：肿瘤微环境在肿瘤发生发展中的作用及分子机制研究
4. 电子邮箱：shengtaozhou@scu.edu.cn
5. 个人简介：
      医学博士，妇产科学教授，研究员，博士生导师，四川大学华西第二医院党委委员。现担任中华医学会妇科肿瘤分会青委副主任委员，中国老年学和老年医学学会妇科分会青委会副主任委员，中国抗癌协会肿瘤微环境委员会青年委员会副主任委员，中国抗癌协会青年理事会常务理事，中国细胞生物学学会细胞代谢分会委员，中国性学会妇产科分会委员，中国优生科学协会肿瘤生殖分会委员，中国优生科学协会生殖道疾病诊治分会青年委员，中国抗癌协会肿瘤标志物专业委员会青年委员。长期从事妇产科一线临床、教学、科研工作，主要研究方向为肿瘤免疫代谢微环境在女性肿瘤发生发展中的分子机制及靶向治疗研究。近年来以通讯作者/第一作者身份在Genome Biology, PNAS，Cancer Research，Oncogene（2018, 2017），Molecular & Cellular Proteomics等国际主流期刊发表SCI学术论文共计30余篇，受邀在Trends in Immunology, Trends in Endocrinology and me-x-tabolism，Endocrine Reviews，Molecular Cancer，Clinical Cancer Research，BBA Reviews on Cancer，Mass Spectrometry Reviews，Cancer Letters等杂志发表综述或评述文章，论文已被Nature Reviews Drug Discovery, Nature Reviews Molecular Cellular Biology，Nature Reviews Disease Primers，Cancer Research等主流杂志评述或引用，其中一篇论文评为ESI高被引论文。目前担任Molecular Cancer杂志副主编，Oncogene杂志Reviews Editor，Springer Nature出版社旗下BMC旗舰刊物Genome Biology, Cell子刊iScience，Mass Spectrometry Reviews, Cancer Letters等SCI杂志编委。参编《New Advances on Disease Biomarkers and Molecular Targets in Biomedicine》一书。
6. 代表性论文论著：

1) Zhao L, Huang S, Mei S, Yang Z, Xu L, Zhou N, Yang Q, Shen Q, Wang W, Le X, Lau   WB, Lau B, Wang X, Yi T, Zhao X, Wei Y, Warner M, Gustafsson JÅ*, Zhou S*. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer me-x-tastasis. Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3673-E3681.
2) Zhao L, Wang W, Huang S, Yang Z, Xu L, Yang Q, Zhou X, Wang J, Shen Q, Wang C, Le X, Feng M, Zhou N, Lau WB, Lau B, Yao S, Yi T, Wang X, Zhao X, Wei Y, Zhou S*. The RNA binding protein SORBS2 suppresses me-x-tastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts. Genome Biol. 2018 Mar 16;19(1):35.
3) Zhao L, Gimple RC, Yang Z, Wei Y, Gustafsson JÅ, Zhou S*. Immunoregulatory functions of nuclear receptors: mechanisms and therapeutic implications. Trends Endocrinol me-x-tab. 2019 Nov 6. pii: S1043-2760(19)30205-X.
4) Zhao L, Hu HB, Gustafsson JÅ, Zhou S*. Nuclear receptors in cancer inflammation and immunity. Trends Immunol. 2020. Feb;41(2):172-185 2020 Feb;41(2):172-185
5) Jiang YT, Wang CD, Zhou S*. Targeting tumor microenvironment in ovarian cancer: Premise and promise. BBA Rev Cancer. 2020 Apr;1873(2):188361
6) YQ Ye, QS Hu, H Chen, K Liang, Y Yuan, Y Xiang, H Ruan, Z Zhang, AR Song, HW Zhang, LX Liu, LX Diao, YY Lou, BY Zhou, L Wang, ST Zhou, JJ Gao, E Jonasch, SH. Lin, Y Xia1, CR Lin, LQ Yang, GB Mills, H Liang, L Han. Characterization of Hypoxia-associated Molecular Features to aid Hypoxia-Targeted Therapy. Nat me-x-tabol. 2019 Apr;1(4):431-444.
7) Xu L, Gimple RC, Wang W, Zhou S*. The present and future of the mass spectrometry-based investigation of the exosome landscape. Mass Spectrom Rev. 2020. In Press
8) Chen Z, Zhang P, Xu Y, Yan J, Liu Z, Lau WB, Lau B, Li Y, Zhao X, Wei Y, Zhou S*. Surgical stress and cancer progression: the twisted tango. Mol Cancer. 2019 Sep 2;18(1):132.
9) Kandimalla R, Gao F, Li Y, Huang H, Ke J, Deng X, Zhao L, Zhou S, Goel A, Wang X. RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level. NPJ Precis Oncol. 2019 May 1;3:13.
10) Zhao L, Zhou S*, Gustafsson JÅ. Nuclear receptors: recent drug discovery for cancer therapies. Endocr Rev. 2019 Mar 14. pii: er.2018-00222.
11) Zhang Q, Zhou NX, Wang W, Zhou ST*. A novel autocrine CXCL14/ACKR2 axis: The Achilles' heel of cancer me-x-tastasis? Clin Cancer Res. 2019 doi: 10.1158/1078-0432.CCR-19-0853.
12) Zhao LJ, Wang W, Xu L, Yi T, Zhao X, Wei YQ, Vermeulen L, Goel A, Zhou ST*, Wang X. Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. Oncogene. 2018 Nov 26. doi: 10.1038/s41388-018-0577-5.
13) Raab M, Sanhaji M, Zhou S, Rödel F, El-Balat A, Becker S, Strebhardt K. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. Neoplasia. 2019 Mar 6;21(4):363-375. doi: 10.1016/j.neo.2019.01.007.
14) Liu Y, Guo JZ, Liu Y, Wang K, Ding W, Wang H, Liu X, Zhou S, Lu XC, Yang HB, Xu C, Gao W, Zhou L, Wang YP, Hu W, Wei Y, Huang C, Lei QY. Nuclear lactate dehydrogenase A senses ROS to produce α-hydroxybutyrate for HPV-induced cervical tumor growth. Nat Commun. 2018 Oct 24;9(1):4429.
15) Wang K, Jiang J, Lei Y, Zhou S, Wei Y, Huang C. Targeting me-x-tabolic-Redox Circuits for Cancer Therapy. Trends Biochem Sci. 2019 Jan 21. pii: S0968-0004(19)30001-5. doi: 10.1016/j.tibs.2019.01.001.
16)  Yang Q, Yang Y, Zhou N, Tang K, Lau WB, Lau B, Wang W, Xu L, Yang Z, Huang S, Wang X, Yi T, Zhao X, Wei Y, Wang H, Zhao L, Zhou S*. Epigenetics in ovarian cancer: premise, properties, and perspectives. Mol Cancer. 2018 Jul 31;17(1):109.
17) L Zhao, G Ji , X Le, Z Luo, C Wang, M Feng, L Xu, Y Zhang, W B Lau, B Lau, Y Yang, L Lei, H Yang, Y Xuan, Y Chen, X Deng, T Yi , S Yao , X Zhao, Y Wei, S Zhou*. An integrated approach identifies STAT4 as a key regulator of ovarian cancer me-x-tastasis. Oncogene. 2017 Jun 15;36(24):3384-3396.
18) Linjie Zhao, Gaili Ji, Xiaobing Le, Chenlu Wang, Lian Xu, Min Feng, Yaguang Zhang, Huiliang Yang, Yu Xuan, Yanfei Yang, Lingzi Lei, Qilian Yang, Wayne Bond Lau, Bonnie Lau, Yi Chen, Xiangbing Deng, Shaohua Yao, Tao Yi, Xia Zhao, Yuquan Wei, Shengtao Zhou*. Long non-coding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Cancer Res. 2017 Mar 15;77(6):1369-1382.
19) Huiliang Yang, Wayne Bond Lau, Bonnie Lau, Yu Xuan, Shengtao Zhou*, Linjie Zhao, Zhongyue Luo, Qiao Lin, Ning Ren, Xia Zhao, Yuquan Wei. A mass spectrometric insight into the origins of benign gynecological disorders. Mass Spectrom Rev. 2017 May;36(3):450-470.
20) Zhou S*, Liu R, Yuan K, Yi T, Zhao X, Huang C, Wei Y. Proteomics analysis of tumor microenvironment: Implications of me-x-tabolic and oxidative stresses in tumorigenesis. Mass Spectrom Rev. 2013 Jul-Aug;32(4):267-311.
21) Zhou S*, Yi T, Liu R, Bian C, Qi X, He X, Wang K, Li J, Zhao X, Huang C, Wei Y. Proteomics identification of annexin A2 as a key mediator in the me-x-tastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics. 2012 Jul;11(7):M112.017988.
22) LJ Zhao, Q Wang, WB Lau, B Lau, Y Xuan, ST Zhou*. Tumor microenvironment: the culprit for ovarian cancer me-x-tastasis. Cancer Lett. 2016 Jul 28;377(2):174-82.
23) Xuan Y, Yang H, Zhao L, Lau WB, Lau B, Ren N, Hu Y, Yi T, Zhao X, Zhou S*, Wei Y. MicroRNAs in colorectal cancer: Small molecules with big functions. Cancer Lett. 2015 May 1;360(2):89-105.
24) Zhao LJ, Zhou ST*, Zou L, Zhao X. The ex-x-pression and functionality of stromal caveolin 1 in human adenomyosis. Hum Reprod. 2013 May;28(5):1324-38. （4.99）
25) Zhou S*, Kuang MC, Zhang BJ, Zhao LJ, Liang Z, Yi T, Huang CH, Wei YQ,     Zhao X. Autophagy in tumorigenesis and cancer therapy: Dr Jekyll or Mr Hyde? Cancer Lett. 2012 Oct 28;323(2):115-27.
26) Zhou S*, Li Y, Huang F, Zhang B, Yi T, Li Z, Luo H, He X, Zhong Q, Bian C, Lin X, Qi X, Liu P, Huang C, Zhao X, Wei Y. Live-attenuated measles virus vaccine confers cell contact loss and apoptosis of ovarian cancer cells via ROS-induced silencing of E-cadherin by methylation. Cancer Lett. 2012 May 1;318(1):14-25.
27) Zhou S*, Liu R, Zhao X, Huang C, Wei Y. Viral proteomics: the emerging cutting-edge of virus research. Sci China Life Sci. 2011 Jun;54(6):502-12.
28) Zhou S*, Huang C, Wei Y. The me-x-tabolic switch and its regulation in cancer cells. Sci China Life Sci. 2010 Aug;53(8):942-58.